Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.74, $0.02 better than the analyst estimate of $0.72. Revenue for the quarter came in at $180.35 million versus the consensus estimate of $184.32 million.

GUIDANCE:

Pacira Pharma sees FY2025 revenue of $730-750 million, versus the consensus of $742.8 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.